Why are you looking at Metaclipse Therapeutics?
Capability
Service linesRESEARCH AND DEVELOPMENT IN NANOTECHNOLOGY · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
Work mix: 100% prime · 0% sub · primary NAICS 541713 / PSC AN12 HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Where they win
Sole agencyRecompete exposure: None
No incumbent recompetes detected in the next 24 months.
Agency buyer map
1 buyersRecompete exposure
NoneNo incumbent recompetes detected in the next 24 months.
No incumbent recompetes detected in the next 24 months.
GET THE FULL BRIEF
Get Metaclipse Therapeutics’s recompete exposure, top agencies and teaming history
The outlook above is free to read and verify — an estimated $355K in play. Enter a work email for two figures the page cannot show.
“With competitive federal procurements, winning starts with strategically understanding the customer environment to the left of SAM.gov. This is what SCOUT does - a deeper and more precise understanding of what the…”
Enter your company name and we'll build the page.
Query this company live in SCOUT via MCP — personalized displacement scoring, alerts, and capture workflow. Learn about SCOUT MCP →
Frequently asked questions
What federal contracts does Metaclipse Therapeutics hold?
Metaclipse Therapeutics (UEI MU6JZBDZR8X1) shows $355K across 1 award actions in SCOUT’s public USASpending-backed profile, with Department of Health and Human Services (HHS) as the top buying agency. Totals cover federal prime awards ≥$100K in the rolling window.
Which agencies does Metaclipse Therapeutics work with?
Metaclipse Therapeutics’s firm-wide obligated mix is led by Department of Health and Human Services (HHS) (100%).
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →